BNET Industries
Market Cap:$140.8M
Last Fiscal Year Sales:$83.0M
- Public
- US
Dow Jones Description
Developer of Drug Products for Eye Diseases & Conditions
President & CEOVicente Anido Jr.
Number of Employees 225
Contact Information
15295 Alton Pkwy
Irvine, California 92618-2315
(949) 788-6000
Peer Companies
NAICS Code In-Vitro Diagnostic Substance Manufacturing: 325413
Recent Events
-
UPDATE 4-Ista wins U.S. panel support for eye itch drug
-
ISTA Pharmaceuticals Announces FDA Advisory Committee to Review Its Bepotastine Ophthalmic Solution, Bepreve - Quick...
-
ISTA Pharmaceuticals Inc. ISTA reports 2nd Quarter ending June 2009 inline with estimates
-
ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results
News & Analysis
Filter by
ista pharmaceuticals inc. - All News and Analysis
A Look at ISTA's Strong Pipeline
Seeking Alpha
- 2009-06-17
Dan Weiss submits: ISTA is a California-based company which has emerged over the past several years to become the fourth largest prescription ophthalmic visual pathway firm in the $5 billion U.S. market. The company currently has three products on the market- by Dan Weiss
OC Drug Makers Disagree with E&Y Financial Survey
- 2008-12-08
AMO Investor Resigns Other Board Position; Irvine Co. Unveils Genetic Test for Baldness Even in this economy, larger drug makers are planning to spend money on research and development, according to a survey by Ernst & Young LLP. But many local companies aren't jumping on that bandwagon. Ernst...
ISTA Pharmaceuticals Inc. Q4 2007 Earnings Call Transcript
Seeking Alpha
- 2008-03-19
Question-and-Answer SessionOperator Ladies and gentlemen, if you wish to ask a question, please press star followed by one on your touch-tone telephone. If your questions have been answered or wish to withdraw your question, please press star followed by two. All questions must be submitted at this time...
A Look into ISTA Pharmaceuticals Inc. - Progressive Coverage.
- 2006-12-14
M2 PRESSWIRE-14 December 2006-www.streetinvesting.com: A Look into ISTA Pharmaceuticals Inc. - Progressive CoverageC1994-2006 M2 COMMUNICATIONS LTD RDATE:14122006 Streetinvesting.com is the author of this release. This release is a result of our current concentration on ISTA Pharmaceuticals Inc. (NASDAQ:ISTA) and their...
Additional Resources
ISTA Pharmaceuticals Announces Positive Results for Phase 2 Study of Low-Dose Bromfenac in Dry Eye Disease
- 2009-06-08
IRVINE, Calif., June 8 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. , today announced positive results from a proof-of-concept Phase 2 clinical study in subjects with dry eye disease keratoconjuctivitis sicca using a new, proprietary, low-dose formulation of bromfenac, the active ingredient in XibromR bromfenac ophthalmic solution 0.09%. The study...
ISTA Pharmaceuticals Announces FDA Advisory Committee to Review Bepreve™ for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
- 2009-06-01
IRVINE, Calif., June 1 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. , today announced it has received notification from the U.S. Food and Drug Administration FDA that the Dermatologic and Ophthalmic Drugs Advisory Committee will review ISTA's New Drug Application NDA for BepreveTM bepotastine ophthalmic solution on June 26, 2009. ...
ISTA Pharmaceuticals' First Quarter 2009 Revenue Increases 32% to $20.4 Million
- 2009-05-07
- First Quarter Operating Loss Reduced to ($4.4) Million in 2009 from ($12.1) Million for the Same 2008 Period - - Ends First Quarter with $52.0 Million in Cash - - Company Reaffirms 2009 Guidance and Continues to Progress Towards Profitability - IRVINE, Calif.,...
ISTA Pharmaceuticals Highlights Bepreve™ Clinical Data at the Association for Research in Vision and Ophthalmology 2009 Annual Meeting
- 2009-05-07
FT. LAUDERDALE, Fla., May 7 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. , today presented results from the Company's BepreveTM bepotastine besilate ophthalmic solution Phase 3 pivotal clinical studies using the Conjunctival Allergen Challenge CAC model of allergic conjunctivitis. The studies demonstrated Bepreve 1.5% was effective at reducing ocular itching...
ISTA Pharmaceuticals Announces Conference Call and Webcast of First Quarter 2009 Financial Results
- 2009-04-17
IRVINE, Calif., April 17 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. , today announced it will release first quarter 2009 financial results on May 7, 2009, and will host a conference call to discuss these results and provide a pipeline update at 5:00 p.m. Eastern Time. Date: Thursday, May...
Research and Markets: ISTA Pharmaceuticals, Inc.: Strategic Analysis Review of One of the Leading Manufacturers of Opthalmis Products
- 2009-04-08
DUBLIN, Ireland -- Research and Markets ( http://www.researchandmarkets.com/research/38982a/ista_pharmaceutica ) has announced the addition of Global Markets Direct's new companyprofile "
- 1
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Vicente Anido Jr. | President & CEO |
| Lauren Silvernail | CFO & Vice President, Corp Dev |
| Kathleen McGinley | Vice President, HR & Corp Services |
| Kirk McMullin | Vice President, Operations |
| Lisa R. Grillone | Vice President, Clinical Res & Medical Affairs |
| Marvin J. Garrett | Vice President, Regulatory Affairs, Quality & Compliance |
| Thomas Mitro | Vice President, Sales & Marketing |
| Timothy R. McNamara | Vice President, Clinical Research & Medical Affairs |
| John W. Chandler | Medical Director |
| Rolf A. Classon | Director |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Richard C. Williams | Chairman |
| Andrew J. Perlman | Board of Directors |
| Benjamin F. McGraw III | Board of Directors |
| Brian H. Dovey | Board Member |
| Dean J. Mitchell | Board of Directors |
| Kathleen D. Laporte | Board of Directors |
| Liza Page Nelson | Board of Directors |
| Peter Barton Hutt | Board of Directors |
| Wayne I. Roe | Board of Directors |
Vicente Anido, Jr., Ph.D.has served as our President and Chief Executive Officer and on our Board of Directors since December 2001. From June 2000 to September 2001, Dr. Anido was general partner for Windamere Venture Partners. From 1996 to 1999, Dr. Anido served as President and Chief Executive Officer of CombiChem, Inc., a biotechnology company. From 1993 to 1996, he served as President of the Americas Region of Allergan, a specialty pharmaceutical company focusing on ophthalmology, dermatology and neuromuscular indications. Dr. Anido is also a director of Apria Healthcare, Inc. Dr. Anido received a Ph.D. in Pharmacy Administration from the University of Missouri.
| Organization | Position | Status |
|---|---|---|
| ISTA Pharmaceuticals, Inc. | President & CEO | Current |
| ISTA Pharmaceuticals, Inc. | Board of Directors | Current |
| Apria Healthcare Group Inc. | Board of Directors | Current |
| Allergan, Inc. | President, Americas Region | Former |
| University of Missouri | Ph.D. in Pharmacy Administration | Former |
| CombiChem, Inc. | President | Former |
| Windamere Venture Partners, LLC | General Partner | Former |
| Organization | Position | Status |
|---|---|---|
| ISTA Pharmaceuticals, Inc. | CFO & Vice President, Corp Dev | Current |
| Organization | Position | Status |
|---|---|---|
| ISTA Pharmaceuticals, Inc. | Vice President, HR & Corp Services | Current |
| The University of Tennessee | M.S. | Former |
| Organization | Position | Status |
|---|---|---|
| ISTA Pharmaceuticals, Inc. | Vice President, Operations | Current |
| Organization | Position | Status |
|---|---|---|
| ISTA Pharmaceuticals, Inc. | Vice President, Clinical Res & Medical Affairs | Current |
| Isis Pharmaceuticals, Inc. | Executive Director, Intellectual Property Licensing | Former |
| New York University | Ph.D. in Cell Biology and Anatomy | Former |
| Organization | Position | Status |
|---|---|---|
| ISTA Pharmaceuticals, Inc. | Vice President, Regulatory Affairs, Quality & Compliance | Current |
| XOMA Corporation | Vice President, Regulatory Affairs and Clinical Research | Former |
| California State University | B.S. in Microbiology | Former |
| Organization | Position | Status |
|---|---|---|
| ISTA Pharmaceuticals, Inc. | Vice President, Sales & Marketing | Current |
| Allergan, Inc. | Vice President, Business Development | Former |
| Organization | Position | Status |
|---|---|---|
| ISTA Pharmaceuticals, Inc. | Vice President, Clinical Research & Medical Affairs | Current |
| Organization | Position | Status |
|---|---|---|
| ISTA Pharmaceuticals, Inc. | Medical Director | Current |
| Organization | Position | Status |
|---|---|---|
| ISTA Pharmaceuticals, Inc. | Chairman | Current |
| Vysis, Inc. | Co-Chairman | Current |
| J-Com | President | Former |
| ISTA Pharmaceuticals, Inc. | Director | Former |
| Vysis, Inc. | Director | Former |
| Cellegy Pharmaceuticals, Inc. | Board of Directors | Former |
| Wharton Graduate School of the University of Pennsylvania | MBA | Former |
| NYSE Group, Inc. | member | Former |
| Organization | Position | Status |
|---|---|---|
| ISTA Pharmaceuticals, Inc. | Board of Directors | Current |
Benjamin F. McGraw, III, Pharm.D. has served on our Board of Directors since April 2000, except for the period from November 2002 to December 2002. Dr. McGraw has been President and Chief Executive Officer since 1994, and Chairman of the Board since 1996, of Valentis, Inc., a biotechnology company. Prior to this, Dr. McGraw was Corporate Vice President for Corporate Development of Allergan. Before that, he was an equity analyst and a fund manager at Carerra Capital Management. Prior to this, he was Vice-President, Development for Marion Laboratories and Marion, Merrell Dow. Dr. McGraw received B.S. and Doctor of Pharmacy degrees from the University of Tennessee Center for the Health Sciences where he also completed a clinical practice residency.
| Organization | Position | Status |
|---|---|---|
| ISTA Pharmaceuticals, Inc. | Board of Directors | Current |
| Urigen Pharmaceuticals, Inc. | Board of Directors | Current |
| Urigen Pharmaceuticals, Inc. | Chairman, President & CEO | Former |
| Allergan, Inc. | Vice President, Corporate Development | Former |
| The University of Tennessee | Pharm.D. | Former |
| Organization | Position | Status |
|---|---|---|
| Domain Associates LLC | Partner | Current |
| Valley Forge Pharmaceuticals, Inc. | Current | |
| The Wistar Institute | Chair | Current |
| Univax Biologics | Chairman | Current |
| Creative BioMolecules, Inc. | Chairman | Current |
| Skinmedica Acne System | Board of Directors | Current |
| Germantown Academy | Board of Directors | Current |
| Biovascular Inc | Board of Directors | Current |
| Ocera Therapeutics, Inc. | Board of Directors | Current |
| Orqis Medical Corporation | Board of Directors | Current |
| Orexigen Co | Board of Directors | Current |
| Align Technology, Inc. | Director | Current |
| Vivus, Inc. | Board Member | Current |
| ISTA Pharmaceuticals, Inc. | Board Member | Current |
| SkinMedica, Inc. | Director | Current |
| Connetics Corporation | Board Member | Current |
| Orexigen Therapeutics, Inc. | Director | Current |
| US Bioscience | Board Member | Current |
| BAS Medical | Director | Current |
| Geron Corporation | Board Member | Current |
| Cardiac Science Corporation | Board Member | Current |
| Trimeris, Inc. | Board Member | Current |
| Resound Corp | Board Member | Current |
| Symphony Medical, Inc. | Director | Current |
| Kauffman Fellows Program at the Center for Venture Education | Director | Current |
| Germantown Academy | Trustee Emeritus | Current |
| Howmedica, Inc. | President | Former |
| Howmet Corporation | President | Former |
| Howmedica, Inc. | management positions | Former |
| Howmet Corporation | management positions | Former |
| Neose Technologies, Inc. | Board of Directors | Current |
| Sanofi-Aventis | Former | |
| Burnham Institute for Medical Research | Board of Directors | Former |
| The Burnham Institute | Board Member | Former |
| Harvard Business School | M.B.A | Former |
| Harvard Business School | M.B.A. degree | Former |
| Colgate University | B.A. | Former |
| Burnham Institute for Medical Research | Trustee | Former |
| Domain Associates LLC | member | Former |
| Organization | Position | Status |
|---|---|---|
| Alpharma, Inc. | President & Chief Executive Officer | Current |
| Alpharma, Inc. | Board of Directors | Current |
| ISTA Pharmaceuticals, Inc. | Board of Directors | Current |
| Guilford Pharmaceuticals, Inc. | Chief Executive Officer | Former |
| Bristol-Myers Squibb Company | President, International | Former |
| Guilford Pharmaceuticals, Inc. | President | Former |
| GlaxoSmithKline Plc | Senior Vice President, Clinical Development & Product Strategy | Former |
| GlaxoSmithKline Plc | Vice President & General Manager, Specialty Divisions, Strategic Planning and Business Development | Former |
| Bristol-Myers Squibb Company | Vice President | Former |
| Coventry University | B.S., Biology | Former |
| City University London | MBA | Former |
| MGI PHARMA Inc. | Board of Directors | Current |
Kathleen D. LaPorte , age 45, has served as a member of the Board of Directors since April 1997. Since July 2005, Ms. LaPorte has been a managing director of New Leaf Venture Partners, a life science venture capital firm. From 1994 to June 2005, Ms. LaPorte was a General Partner at the Sprout Group, a venture capital firm affiliated with Credit Suisse First Boston. Ms. LaPorte currently serves on the board of directors of Affymax, Inc., a publicly traded biopharmaceutical company, eHealth, Inc., a publicly traded healthcare technology company, ISTA Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, Adeza Biomedical Corporation, a publicly traded medical device company, and several privately-held companies. Ms. LaPorte holds a B.S. in Biology from Yale University and an M.B.A. from the Stanford University Graduate School of Business.
| Organization | Position | Status |
|---|---|---|
| New Leaf Venture Partners | Managing Director | Current |
| Sprout Group | General Partner | Former |
| Fullterm | Director | Current |
| Insureco Marketing LLC | Director | Current |
| Prometheus Laboratories, Inc. | Board of Directors | Current |
| Cellgate, Inc | Board of Directors | Current |
| ISTA Pharmaceuticals, Inc. | Board of Directors | Current |
| Affymax, Inc. | Board of Directors | Current |
| Adeza Biomedical Corporation | Board of Directors | Current |
| Ardea Biosciences, Inc.De | Board of Directors | Current |
| Adeza | Director | Current |
| TransOral Pharmaceuticals, Inc. | Board Member | Current |
| Western Association of Venture Capitalists | Past President | Former |
| New Leaf Venture Partners | Founder | Former |
| Credit Suisse | General Partner | Former |
| Asset Management Company | Principal | Former |
| Stanford Graduate School of Business | M.B.A. | Former |
| Western Association of Venture Capitalists | Member of the Board | Current |
| Yale University | BS Degree | Former |
| Adeza Biomedical Corporation | member | Former |
| Organization | Position | Status |
|---|---|---|
| Investor Growth Capital, Inc. | Managing Director | Current |
| Health Care, Inc. | Co-Head | Current |
| Sirion Therapeutics, Inc. | Board Member | Current |
| Kai Pharmaceuticals, Inc | Board of Directors | Current |
| Ception Therapeutics, Inc. | Board of Directors | Current |
| Biolex, Inc. | Board of Directors | Current |
| Epigenesis Pharmaceuticals, LLC | Board Member | Current |
| Solstice Neurosciences, Inc. | Board Member | Current |
| Ceregene, Inc. | Board Member | Current |
| Investor Growth Capital, Inc. | Board of Directors | Current |
| Molecular Staging, Inc. | Board of Directors | Current |
| ISTA Pharmaceuticals, Inc. | Board of Directors | Current |
| Pfizer Inc. | Senior Operating Head | Former |
| Yale University | M.B.A. In Finance and Marketing | Former |
| Yale School of Management | M.B.A. In Finance and Marketing | Former |
| Wesleyan University | B.A. In Economics | Former |
Peter B. Hutt, who previously served on our Board of Directors, has been appointed to serve as a special advisor to the Chairman of the Board, specifically to consult on Food and Drug Administration matters. Since 1965, Mr. Hutt has been a partner at the law firm of Covington & Burling, where he specializes in food and drug law. Mr. Hutt served as Chief Counsel for the Food and Drug Administration from 1971 to 1975 and has taught courses on food and drug law at Harvard Law School and Stanford Law School.
| Organization | Position | Status |
|---|---|---|
| Covington & Burling | Partner | Current |
| Proseed Capital Holdings CVA | Partner | Current |
| Incube Ventures | Partner | Current |
| Favrille, Inc. | Partner | Current |
| Forward Ventures | Partner | Current |
| Food Company, Inc. | Co-Author | Current |
| National Academy of Sciences | Current | |
| Magen Biosciences, Inc | Board of Directors | Current |
| Forward Ventures | Director | Current |
| Genocea | Board of Directors | Current |
| NuVim, Inc. | Board of Directors | Current |
| Incube Ventures | Board of Directors | Current |
| ISTA Pharmaceuticals, Inc. | Board of Directors | Current |
| Chicago Growth Partners | Director | Current |
| Ranexa | Director | Current |
| Lifeheart.Com | Director | Current |
| Aeras and Partners | Board of Directors | Current |
| XOMA Corporation | Board of Directors | Current |
| Kearny Venture Partners | Board of Directors | Current |
| U.S. Food and Drug Administration | Chief Counsel | Former |
| Rituxan | Director of Other Companies | Former |
| Momenta Pharmaceuticals, Inc. | Committee Chair for Nominating and Governance Committee | Former |
| New York University | Ll.M. In Food | Former |
| New York University School of Law | Master of Laws Degree In Food and Drug Law | Former |
| Harvard Law School | L.L.B. | Former |
| Yale University | B.A. Degree | Former |
| New York University | Degrees | Former |
| Harvard University | Degrees | Former |
| Yale College | Former | |
| Introgen Therapeutics, Inc. | member | Former |
| Organization | Position | Status |
|---|---|---|
| Healthcarereps.Com | Current | |
| Xanodyne Pharmaceuticals, Inc. | Chairman of the Board of Directors | Current |
| Hillenbrand Industries, Inc. | Chairman | Current |
| Auxilium Pharmaceuticals, Inc. | Chairman of The Board of Directors | Current |
| Bayer HealthCare, Animal Health Division | Chairman | Current |
| Hill-Rom Company, Inc. | Chairman, Hill, Rom Holdings, Inc., Batesville, In | Current |
| Prometheus Laboratories, Inc. | Board of Directors | Current |
| Esgro and Lif Resource Center | Board of Directors | Current |
| Eurand America, Inc. | Board of Directors | Current |
| Millipore Corporation | Board of Directors | Current |
| PharmaNet Inc. | Board of Directors | Current |
| Clinical Trials Today | Director | Current |
| ISTA Pharmaceuticals, Inc. | Director | Current |
| Enzon Pharmaceuticals, Inc. | Board of Directors | Current |
| Millipore Corporation | Committee Member | Current |
| Hillenbrand, Inc. | Chief Executive Officer | Former |
| Hillenbrand Industries, Inc. | Chief Executive Officer | Former |
| Bayer HealthCare, Animal Health Division | Chief Executive Officer | Former |
| Hillenbrand, Inc. | Interim President | Former |
| Pharmacia Corporation | President | Former |
| Bayer HealthCare, Animal Health Division | President | Former |
| Hillenbrand Industries, Inc. | President | Former |
| Pharmacia Corporation | Chief Operating Officer | Former |
| Bayer Corporation | Executive Vice President | Former |
| Bayer Healthcare AG | Chairman | Former |
| Auxilium Pharmaceuticals, Inc. | Director | Former |
| Pharmanet Development Group, Inc. | Board of Directors | Former |
| University of Gothenburg | Business Degree | Former |
| Enzon Pharmaceuticals, Inc. | member | Former |
| Organization | Position | Status |
|---|---|---|
| Aradigm Corporation | Consultant and Director | Current |
| Aderis Pharmaceuticals, Inc. | Board of Directors | Current |
| Intrapace, Inc | Board of Directors | Current |
| IntraPace, Inc. | Board of Directors | Current |
| Chicago Growth Partners | Director | Current |
| ISTA Pharmaceuticals, Inc. | Board of Directors | Current |
| Forward Ventures | Director | Current |
| Favrille, Inc. | Director | Current |
| Aradigm Corporation | Board of Directors | Current |
| Percusurge, Inc. | Director | Current |
| United Therapeutics Corporation | Senior Vice President of Product Economics and Health Policy | Former |
| XOMA Corporation | Vice President, Regulatory Affairs and Clinical Research | Former |
| ISTA Pharmaceuticals, Inc. | Director, Aradigm Corporation | Former |
| Health Care Financing Administration | Board of Directors | Former |
| State University of New York at Albany | M.A. | Former |
| The State University of New York | M.A. | Former |
| University of Maryland | M.A. | Former |
| Union College | B.A. | Former |
| California State University | B.S. in Microbiology | Former |
Executive News
-
Dermatologic and Ophthalmic Drugs Advisory Committee Unanimously Recommends Bepreve(TM) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
-
ISTA Pharmaceuticals Announces Positive Results for Phase 2 Study of Low-Dose Bromfenac in Dry Eye Disease
-
ISTA Pharmaceuticals, Inc. (ISTA) Announces Positive Results for Phase 2 Study of Low-Dose Bromfenac in Dry Eye Disease
-
Xanodyne Announces New President/CEO and Completes $38 Million Equity Financing
-
ISTA Pharmaceuticals Announces Positive Results for Phase 2 Study of Low-Dose Bromfenac...
-
ISTA Pharmaceuticals Announces Positive Results for Phase 2 Study of Low-Dose Bromfenac in Dry Eye Disease
-
Xanodyne Pharmaceuticals, Inc. Announces New President/CEO and Completes $38 Million Equity Financing
-
Xanodyne Announces New President/CEO and Completes $38 Million Equity Financing
-
Xanodyne Announces New President/CEO and Completes $38 Million Equity Financing
-
Xanodyne Announces New President/CEO and Completes $38 Million Equity Financing
-
Xanodyne announces new president, equity financing
-
Drug Agency May Reveal More Data on Actions
Industry Transcripts by Seeking Alpha
-
BMP Sunstone Corporation Q1 2009 Earnings Call Transcript
on Jun 30, 2009about BJGP
-
Matrixx Initiatives, Inc., F4Q09 (Qtr End 03/31/09) Earnings Call Transcript
on May 12, 2009about MTXX
-
King Pharmaceuticals Inc., Q1 2009 Earnings Call Transcript
on May 11, 2009about KG
-
Flamel Technologies SA Q1 2009 Earnings Call Transcript
on May 11, 2009about FLML
-
Sucampo Pharmaceuticals, Inc. Q1 2009 Earnings Call Transcript
on May 08, 2009about SCMP
Glass Door
Pharma Industry Companies
| Company | Employer Rating |
| Pfizer |  |
IndustryTop Rated
- AstraZeneca's Seroquel Research Director Confessed to Sex-for-Studies Affairs 17 votes
- Forest Labs' Lexapro Flap Over JAMA Article Will Likely Be Examined by the Feds 11 votes
- Medarex Execs Got 10% Pay Raise Despite Delivering Nothing 11 votes
- Schering CEO Hassan Has $59 Million Buyout Agreement in Merck Merger 10 votes
- Gilead Whistleblower Suit: A Bullet Dodged 10 votes
